glp-1 weight loss drug news november 2025 How Supply and Demand for Drugs is Playing Out in 2026 🚨 Breaking News in Obesity

Both compounds require gradual dose escalation

Available at: 144 Boehringer Ingelheim

When you stop retatrutide, glucagon receptor stimulation ends and metabolic rate returns to baseline

1 Introduction In the past decade, obesity and related co-morbidities have become critical public health problems and serious medical conditions worldwide (1)

The prevalence of thyroid dysfunction is significantly higher among patients with T2DM compared with the general population [5]

As more GLP-1 prescriptions are written to manage not just diabetes and cardiovascular disease but also obesity, a key question emerges: What is the role of patient engagement and chronic disease management when prescribing these drugs